Hepatitis A Vaccines (Hepatitis A Vaccine)

01/01/2009 - "Hepatitis A vaccines have been highly effective in preventing hepatitis A. "
02/01/2004 - "Improved understanding of the epidemiology and transmission of hepatitis A combined with the availability of effective hepatitis A vaccines have dramatically reduced the burden of hepatitis A in the United States."
08/13/1992 - "The inactivated purified hepatitis A vaccine that we tested is well tolerated, and a single dose is highly protective against clinically apparent hepatitis A."
10/29/2014 - "Benefiting from the booming economy, rapid improvement in sanitation, safe water supply, and implementation of hepatitis A vaccines, the epidemiological pattern of hepatitis A moved from high to intermediate endemicity in Shijiazhuang. "
10/01/2007 - "Positive results showed that it was successful to use hepatitis A vaccine as the strategy to prevent and control hepatitis A in the past five years in Tianjin."

11/01/1998 - "The recent availability and proven efficacy of a hepatitis A vaccine offers the hope that the incidence of infection may be substantially reduced. "
12/01/1997 - "Hepatitis A vaccine has been found to be effective in reducing the incidence of infection in travelers. "
01/01/1996 - "The inactivated hepatitis A vaccine is safe, clinically well tolerated, and provides long-term protection against HAV infection. "
03/21/2001 - "A randomised controlled trial of hepatitis A vaccine in household contacts of people with sporadic HAV infection in Italy has shown a protective efficacy of 82% (CI 20-96%). "
01/28/1999 - "In conclusion, inactivated hepatitis A vaccine is safe and immunogenic in children, the duration of protection against HAV infection is longer than five years."

12/07/2006 - "Hepatitis A vaccine is both safe and effective in this small studied group of children with chronic liver disease. "
12/07/2006 - "To study the safety and efficacy of hepatitis A vaccine (HAV) in children with chronic liver disease of various etiologies. "
12/07/2006 - "Safety and efficacy of hepatitis A vaccine in children with chronic liver disease."
06/01/1997 - "Thus, an inactivated hepatitis A vaccine was safe in patients with chronic liver disease while the immune response was inferior to that observed in healthy subjects reported in a previous study."
03/01/2016 - "In conclusion, we recommend that patients younger than 40 years and/or those living in cities and having a chronic liver disease should be vaccinated with the hepatitis A vaccine."

05/01/1995 - "Inactivated hepatitis A vaccines appear to be highly effective in preventing clinical hepatitis and controlling epidemics. "
06/22/2015 - "Our study suggests that the introduction of two-dose hepatitis A vaccines in Panama has contributed to the reduction in the incidence of overall hepatitis-related outcomes for all age groups, suggesting herd protection. "
07/24/2015 - "Improvements in water quality and sanitation as well as inclusion of hepatitis A vaccine in childhood immunization programs should be considered to reduce the public health burden of hepatitis in India. "
05/01/2009 - "The series of coincidences that led to my involvement in the field of viral hepatitis and the circuitous pathway leading to the development of the first hepatitis A vaccine is described from a personal perspective."
01/01/2006 - "Long-term protective effect of post-exposure Havrix administration during viral hepatitis Type A outbreaks."

12/01/2002 - "Hepatitis A vaccine has been shown to be cost effective when given to children in regions with high attack rates and to patients with chronic hepatitis C. "
03/01/1998 - "In conclusion, hepatitis A vaccine was well tolerated and induced a satisfactory immune response in patients with chronic hepatitis B, chronic hepatitis C, and miscellaneous CLD."
03/01/1998 - "Although a higher percentage of healthy subjects (93%) seroconverted after a single dose of the hepatitis A vaccine than did subjects with chronic hepatitis C (73.7%) or CLD of nonviral etiologies (83.1%), more than 94% of all vaccinees were seropositive for anti-HAV after the complete vaccination course. "
03/01/1998 - "A secondary objective was to compare the safety of the hepatitis A vaccine with that of a commercial hepatitis B vaccine in subjects with chronic hepatitis C. "
05/01/2000 - "The safety and immunogenicity of an inactivated hepatitis A vaccine was evaluated in a study involving 60 patients with chronic liver disease (CLD) (56 patients with chronic hepatitis B, and four patients with chronic hepatitis C). "